SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/26/10 Shire plc 10-K 12/31/09 62:8.1M Davis Polk & … LLP 01/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 2.87M 2: EX-10.26 Material Contract HTML 37K 3: EX-21 Subsidiaries List HTML 47K 4: EX-23.1 Consent of Experts or Counsel HTML 19K 5: EX-23.2 Consent of Experts or Counsel HTML 19K 6: EX-31.1 Certification -- §302 - SOA'02 HTML 26K 7: EX-31.2 Certification -- §302 - SOA'02 HTML 26K 8: EX-32.1 Certification -- §906 - SOA'02 HTML 20K 47: XML IDEA XML File -- Definitions and References XML 131K 55: XML IDEA XML File -- Filing Summary XML 94K 52: XML.R1 Document And Entity Information XML 89K 53: XML.R2 Consolidated Balance Sheets XML 268K 32: XML.R3 Consolidated Balance Sheets (Parentheticals) XML 57K 37: XML.R4 Consolidated Balance Sheets (Parentheticals in XML 33K GBP) 45: XML.R5 Consolidated Statements of Operations XML 365K 44: XML.R6 Consolidated Statements of Operations XML 51K (Parentheticals) 59: XML.R7 Consolidated Statement of Changes in Shareholders' XML 1.03M Equity 22: XML.R8 Consolidated Statements of Comprehensive Income XML 122K 43: XML.R9 Components of Accumulated Other Comprehensive XML 51K Income 20: XML.R10 Consolidated Statements of Comprehensive Income XML 59K (Parentheticals) 19: XML.R11 Consolidated Statements of Cash Flows XML 545K 31: XML.R12 Description Of Operations XML 35K 49: XML.R13 Summary Of Significant Accounting Policies XML 80K 33: XML.R14 Business combinations XML 79K 34: XML.R15 Termination costs XML 38K 41: XML.R16 Gain on sale of product rights XML 35K 62: XML.R17 Reorganization costs XML 43K 29: XML.R18 Intergration and Acquisition costs XML 35K 15: XML.R19 Accounts receivable, net XML 38K 36: XML.R20 Inventories XML 37K 48: XML.R21 Assets held for sale XML 35K 25: XML.R22 Prepaid expenses and other current assets XML 37K 46: XML.R23 Investments XML 40K 35: XML.R24 Property Plant and Equipment, net XML 38K 58: XML.R25 Goodwill XML 39K 51: XML.R26 Other intangible assets, net XML 43K 38: XML.R27 Accounts payable and accrued expenses XML 43K 42: XML.R28 Other current liabilities XML 37K 18: XML.R29 Long-term debt XML 40K 21: XML.R30 Other long-term debt XML 36K 26: XML.R31 Other non-current liabilities XML 37K 30: XML.R32 Derivative instruments XML 45K 40: XML.R33 Fair value measurement XML 53K 50: XML.R34 Commitments and contingencies XML 56K 17: XML.R35 Shareholders Equity XML 41K 23: XML.R36 Earnings per share XML 52K 54: XML.R37 Segmental reporting XML 97K 57: XML.R38 Interest expense XML 36K 39: XML.R39 Other income (expenses), net XML 39K 60: XML.R40 Retirement benefits XML 34K 24: XML.R41 Taxation XML 86K 61: XML.R42 Share-based compensation plans XML 71K 28: XML.R43 Restatement of previously issued financial XML 35K statements 16: XML.R44 Income Access Share Trust Financial Statements XML 62K 27: XML.R45 Valuation and Qualifying Accounts Schedule XML 45K 56: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 206K 9: EX-101.INS XBRL Instance -- shpgf-20091231 XML 826K 11: EX-101.CAL XBRL Calculations -- shpgf-20091231_cal XML 203K 12: EX-101.DEF XBRL Definitions -- shpgf-20091231_def XML 86K 13: EX-101.LAB XBRL Labels -- shpgf-20091231_lab XML 822K 14: EX-101.PRE XBRL Presentations -- shpgf-20091231_pre XML 468K 10: EX-101.SCH XBRL Schema -- shpgf-20091231 XSD 99K
Subsidiary/undertaking
|
Jurisdiction
of incorporation
|
|
3829359
Canada Inc.
|
Canada
|
|
Monmouth
Pharmaceuticals Limited
|
United
Kingdom
|
|
Pharma
International Insurance Limited
|
Ireland
|
|
Rybar
Laboratories Limited
|
United
Kingdom
|
|
Shire 2005
Investments Limited
|
Cayman
Islands
|
|
Shire
Acquisition Inc
|
Canada
|
|
Shire
Australia Pty Limited
|
Australia
|
|
Shire Belgium
BVBA
|
Belgium
|
|
Shire
Biopharmaceuticals Holdings
|
United
Kingdom
|
|
Shire
Biopharmaceuticals Ireland Limited
|
Ireland
|
|
Shire
Biopharmaceuticals Ireland No.2 Limited
|
Ireland
|
|
Shire Canada
Inc.
|
Canada
|
|
Shire
Deutschland GmbH
|
Germany
|
|
Shire
Deutschland Investments GmbH
|
Germany
|
|
Shire
Development Inc
|
United
States
|
|
Shire Europe
Finance
|
United
Kingdom
|
|
Shire Europe
Limited
|
United
Kingdom
|
|
Shire
Executive Services LLC
|
United
States
|
|
Shire Finance
Limited
|
Cayman
Islands
|
|
Shire France
S.A.
|
France
|
|
Shire Global
Finance
|
United
Kingdom
|
|
Shire Hellas Pharmaceuticals Import Export and
Marketing S.A.
|
Greece
|
|
Shire
Holdings AG
|
Switzerland
|
|
Shire
Holdings Europe B.V.
|
Netherlands
|
|
Shire
Holdings Europe Limited
|
United
Kingdom
|
|
Shire
Holdings Europe No.2 S.a.r.l.
|
Luxembourg
|
|
Shire
Holdings Ireland Limited
|
Ireland
|
|
Shire
Holdings Ireland No.2 Limited
|
Ireland
|
|
Shire
Holdings Limited
|
Bermuda
|
|
Shire
Holdings UK Canada Limited
|
United
Kingdom
|
|
Shire
Holdings UK Limited
|
United
Kingdom
|
|
Shire
Holdings US AG
|
United
States
|
|
Shire Human
Genetic Therapies (Canada) Inc.
|
Canada
|
|
Shire Human
Genetic Therapies AB
|
Sweden
|
|
Shire Human
Genetic Therapies SA
|
Argentina
|
|
Shire Human
Genetic Therapies Inc
|
United
States
|
|
Shire Human
Genetic Therapies Limited
|
United
Kingdom
|
|
Shire Human
Genetic Therapies Farmaceutica Ltda
|
Brazil
|
|
Shire Human
Genetic Therapies Securities Corporation
|
United
States
|
|
Shire Human
Genetic Therapies UK Limited
|
United
Kingdom
|
|
Shire
Incorporated
|
United
States
|
|
Shire
Intellectual Property 2 SRL
|
Barbados
|
|
Shire
Intellectual Property Ireland Limited
|
Ireland
|
|
Shire
Intellectual Property SRL
|
Barbados
|
|
Shire
International Licensing BV
|
Netherlands
|
|
Shire
Investments & Finance (U.K.) Company
|
United
Kingdom
|
|
Shire IP
Services Corporation
|
Canada
|
|
Shire Italia
S.p.A.
|
Italy
|
|
Shire Jersey
Limited
|
Jersey
|
|
Shire
LLC
|
United
States
|
|
Shire Luxembourg Intellectual
Property No.2 S.a r.l.
|
Luxembourg
|
|
Shire Luxembourg Intellectual
Property S.a r.l.
|
Luxembourg
|
|
Shire
Luxembourg Sarl
|
Luxembourg
|
|
Shire
Pharmaceutical Contracts Limited
|
United
Kingdom
|
|
Shire
Pharmaceutical Development Inc
|
United
States
|
Shire
Pharmaceutical Development Limited
|
United
Kingdom
|
|
Shire
Pharmaceutical Holdings Ireland Limited
|
Ireland
|
|
Shire
Pharmaceutical Investment Holdings Limited
|
Malta
|
|
Shire
Pharmaceutical Investment Limited
|
Malta
|
|
Shire
Pharmaceutical Investment Trading Ireland
|
Ireland
|
|
Shire
Pharmaceutical Investments 2008
|
Ireland
|
|
Shire
Pharmaceuticals Group
|
United
Kingdom
|
|
Shire
Pharmaceuticals Iberica S.L.
|
Spain
|
|
Shire
Pharmaceuticals Inc
|
United
States
|
|
Shire
Pharmaceuticals Investments (British Virgin Islands)
Limited
|
Virgin
Islands, British
|
|
Shire
Pharmaceuticals Investments 2007
|
Ireland
|
|
Shire
Pharmaceuticals Ireland Limited
|
Ireland
|
|
Shire
Pharmaceuticals Limited
|
United
Kingdom
|
|
Shire
Pharmaceuticals Mexico SA de CV
|
Mexico
|
|
Shire
Pharmaceuticals Services Limited
|
United
Kingdom
|
|
Shire
Properties US
|
United
States
|
|
Shire
Regulatory Inc
|
United
States
|
|
Shire
Supplies U.S. LLC
|
United
States
|
|
Shire UK
Investments Limited
|
United
Kingdom
|
|
Shire US
Holdings Inc.
|
United
States
|
|
Shire US
Inc
|
United
States
|
|
Shire US
Investments
|
United
Kingdom
|
|
Shire US
Manufacturing Inc
|
United
States
|
|
Sparkleflame
Limited
|
United
Kingdom
|
|
Tanaud
International BV
|
Netherlands
|
|
Tanaud
Ireland Inc.
|
Ireland
|
|
The Endocrine
Centre Limited
|
United
Kingdom
|
|
TKT Argentina
srl
|
Argentina
|
|
Jerini
AG
|
Germany
|
|
Jerini US,
Inc.
|
United
States
|
|
JPT Peptide
Technologies, Inc.
|
United
States
|
|
Jerini
Ophthalmic Holding GmbH
|
Germany
|
|
Jerini
Ophthalmic, Inc.
|
United
States
|
|
Jerini
Beteiligungen GmbH
|
Germany
|
|
Jerini
Holding Limited
|
Malta
|
|
Jerini
Trading Limited
|
Malta
|
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/25/10 SEC UPLOAD¶ 9/11/17 1:21K Shire plc 4/14/10 SEC UPLOAD¶ 9/11/17 1:31K Shire plc |